Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial-Reference-Cited by-同舟云学术

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

Published:2015-01 Issue:1 Volume:16 Page:87-97
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Oza Amit M,Cibula David,Benzaquen Ana Oaknin,Poole Christopher,Mathijssen Ron H J,Sonke Gabe S,Colombo Nicoletta,Špaček Jiří,Vuylsteke Peter,Hirte Holger,Mahner Sven,Plante Marie,Schmalfeldt Barbara,Mackay Helen,Rowbottom Jacqui,Lowe Elizabeth S,Dougherty Brian,Barrett J Carl,Friedlander Michael

Publisher

Elsevier BV

Subject

Oncology

Reference32 articles.

1. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012;Ferlay;Eur J Cancer,2013

2. Optimal chemotherapy treatment for women with recurrent ovarian cancer;Fung-Kee-Fung;Curr Oncol,2007

3. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial;Parmar;Lancet,2003

4. Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature;Gadducci;Crit Rev Oncol Hematol,2005

5. Management of platinum-sensitive recurrent ovarian cancer;Pfisterer;Semin Oncol,2006

Cited by 475 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

2. Neurological toxicities with poly (ADP-ribose) polymerase inhibitors in cancer patients: a systematic review and meta-analysis;Journal of Chemotherapy;2024-08-23

3. Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer;Frontiers in Oncology;2024-07-29

4. Combining inotuzumab ozogamicin with PARP inhibitors olaparib and talazoparib exerts synergistic cytotoxicity in acute lymphoblastic leukemia by inhibiting DNA strand break repair;Oncology Reports;2024-05-21

5. A systematic review of ethnic minority participation in randomised controlled trials of systemic therapies for gynecological cancers;Gynecologic Oncology;2024-05